NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders, and certain oncological diseases. The company’s leading clinical candidate, 17α-ethynyl-androst-5-ene-3b,7b,17b-triol, compound code NE3107 is a small molecule, orally administered, anti-inflammatory, insulin-sensitizing agent with a novel mechanism of action i...
NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders, and certain oncological diseases. The company’s leading clinical candidate, 17α-ethynyl-androst-5-ene-3b,7b,17b-triol, compound code NE3107 is a small molecule, orally administered, anti-inflammatory, insulin-sensitizing agent with a novel mechanism of action is entering a pivotal phase 3 clinical trial for the treatment of mild to moderate Alzheimer’s disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.